[Successful management of massive gastrointestinal bleeding using recombinant factor VIIa in an elderly patient with respiratory and renal failure]
Related Experiment Video
Updated: Apr 25, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Minlong Liu1, Guoen Wang, Qi Ma
1Department of Intensive Care Medicine, Second Affiliated Hospital, Xi'an Jiaotong University College of Medicine, Xi'an 710004, China.E-mail: liuminlong2010@sina.cn.
Abstract:
Recombinant activated factor VII (rFVIIa) is a novel therapeutic agent for life-threatening massive gastrointestinal bleeding. We report a case of massive gastrointestinal bleeding in a 78-year-old female patient with respiratory and renal failure. After failure of management of the bleeding with routine pharmacotherapy, we gave the patient rFVIIa injection at the dose of 20 µg/kg and the bleeding was rapidly controlled. Adverse side effects of the drug were not observed in this patient.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Pulmonary Embolism III: Nursing Management

